Ipamorelin vs CJC-1295 no DAC vs Tesamorelin

A growth hormone secretagogue is any compound that prompts the pituitary to release its own growth hormone (GH) rather than supplying GH from outside the body. Ipamorelin, CJC-1295 (no DAC) and tesamorelin are three of the most-studied secretagogues in the research catalogue, and they are not variations on one molecule — they reach the same pituitary cells through two different receptor systems. This article compares them for research identification only. It makes no claims about human use, benefit, or dosing, and it does not describe how to administer anything.

Two receptor families, one target cell

Every compound here acts on the somatotroph cells of the anterior pituitary — the cells that store and release GH. What differs is the door each one knocks on. Two distinct receptor families feed that same cell, and the whole comparison hinges on telling them apart.

The first is the growth-hormone-releasing hormone (GHRH) receptor. It is a Gs-coupled receptor: when a GHRH-type peptide binds, it activates adenylyl cyclase, raises intracellular cAMP, and primes GH synthesis and release. CJC-1295 (no DAC) and tesamorelin are both GHRH-receptor agonists — synthetic analogues built from the natural GHRH sequence.

The second is the ghrelin receptor, GHS-R1a — the target of the growth-hormone-releasing peptides, or GHRPs. This receptor is Gq-coupled: activation drives phospholipase C signalling and a rise in intracellular calcium, which triggers exocytosis of stored GH granules. Ipamorelin is a GHRP, working through GHS-R1a rather than the GHRH receptor.

Because these are two separate second-messenger systems — cAMP on one side, calcium on the other — that happen to converge on one cell type, GHRH and GHRP compounds are studied as complementary tools rather than substitutes. That distinction runs through everything below.

Ipamorelin: a selective GHRP

Ipamorelin is a synthetic pentapeptide that binds GHS-R1a with high selectivity. Its notable feature in the published record is a clean endocrine profile. Earlier peptidyl secretagogues such as GHRP-2 and GHRP-6 also stimulate ACTH and cortisol; in the original characterisation study, ipamorelin released GH with potency comparable to GHRP-6 across rat pituitary cells, anaesthetised rats, and conscious swine, yet did not raise ACTH or cortisol beyond what GHRH stimulation produced (Raun, Eur J Endocrinol, 1998). That separation is what earned it the "selective" label, and it is why ipamorelin often appears as a control or comparator compound in GH-axis work where a cortisol spike would confound the readout.

Its half-life is roughly two hours in human pharmacokinetic modelling, longer than the GHRH analogues below, which shapes how researchers slot it into a study design. The calcium-driven signal it produces is a discrete, pulsatile GH release rather than a sustained elevation.

CJC-1295 (no DAC): a short-acting GHRH analogue

CJC-1295 (no DAC), also known as Modified GRF 1-29, is the GHRH(1-29) active fragment carrying four amino-acid substitutions — D-Ala², Gln⁸, Ala¹⁵, and Leu²⁷ — that harden it against enzymatic breakdown. That engineering exists because native GHRH is a poor research tool: plasma dipeptidyl peptidase-IV (DPP-IV) clips its first two residues almost immediately, and the intact peptide was measured with an in-vivo half-life of about 6.8 minutes (Frohman, J Clin Invest, 1986). A D-amino-acid substitution at position 2 blocks that cleavage, which is exactly what the D-Ala² change accomplishes.

The critical qualifier is "no DAC." The Drug Affinity Complex is a maleimide group that covalently tethers the peptide to serum albumin, producing a fundamentally different, long-lived molecule with a measured half-life of 5.8 to 8.1 days (Teichman, J Clin Endocrinol Metab, 2006). The no-DAC form here has no such tether: it clears in the minutes range, so in study models it reinforces the pituitary's own pulsatile GH rhythm rather than holding GH continuously elevated. A protocol that specifies one form cannot silently swap in the other.

Tesamorelin: a full-length GHRH analogue

Tesamorelin is a stabilised analogue of the full 44-residue hormone, GHRH(1-44), carrying an N-terminal trans-3-hexenoyl group that blocks the same DPP-IV cleavage site — a different structural answer to the same degradation problem CJC-1295 solves with backbone substitutions. It engages the GHRH receptor and drives GH release in the body's own pulsatile pattern, extending the circulating half-life to roughly 26–38 minutes in human pharmacokinetics.

It is the one member of this family to have completed a full phase 3 programme. In a 26-week randomised placebo-controlled trial of HIV-positive patients with excess abdominal fat, tesamorelin was associated with a measured reduction in visceral adipose tissue and a rise in IGF-1 versus placebo (Falutz et al., NEJM, 2007), a finding echoed in a later pooled analysis of two trials (Falutz et al., J Clin Endocrinol Metab, 2010). That trial record is the reason tesamorelin is a useful reference comparator when a research question turns on evidence quality. Note that the branded medicine Egrifta is a separate, approved product — the material discussed here is research-grade and is not that medicine.

Side-by-side comparison

Why GHRH and GHRP compounds are studied together

Because a GHRH agonist and a GHRP agonist act on independent receptors on the same somatotroph cell, pairing one from each family is a standard design in GH-axis research. The GHRH side raises cAMP and primes the cell; the GHRP side raises calcium and drives granule release. Studied in combination, the two signals have been reported to produce a larger, still-pulsatile GH pulse than either alone — which is precisely why receptor-convergence models keep appearing in the literature. Understanding which receptor family a compound belongs to is the first step in reading any of that work, and it is why these three sit together in our growth-hormone-axis signalling category.

Handling and storage in Thailand

Solvent and storage choices are formulation- and protocol-specific; the three compounds should not be assigned one generic procedure. Use the laboratory reconstitution guide and Thailand storage guide to plan compatibility checks, receipt records, and excursions, then follow material-specific evidence.